Positive impactCompany
Glenmark Pharma's India-US Growth Story Intact, Says Motilal Oswal, Maintaining 'Buy' — Check Target Price
NDTV Profit 4 hrs ago·4 Aug 2026, 1:53 am
Glenmark Pharma has received a vote of confidence from Motilal Oswal, which has maintained its 'Buy' rating on the stock. The brokerage firm highlighted that the company's growth trajectory remains intact, driven by strong performance across key business segments. This includes a robust showing in the domestic branded formulation market, consumer care, and significant expansion in North America and emerging markets.
For investors, this positive outlook suggests that Glenmark's diversified strategy is paying off. The brokerage's decision to keep the target price unchanged indicates confidence in the company's ability to navigate competitive pressures and sustain its momentum. Investors should monitor upcoming quarterly results to see if this momentum continues to build.
Key takeaways
- Category: Company.
- AI reads the tone as positive (potentially bullish) for the stock.
Why it matters
A routine update. The tone is positive — historically associated with upward pressure, though not predictive. Use the price and stock snapshot to gauge how the market is responding.
